Everest Medicines Hosts Second mRNA R&D Day as Self-Developed Platform Enters Clinical Validation Phase

Stock News11-04

Recently, Everest Medicines (01952) held its 2026 mRNA Technology Platform R&D Day in Shanghai, marking the second consecutive year the company has centered its event on its proprietary mRNA platform to disclose technical iterations and pipeline progress. At the event, Everest Medicines systematically presented its mRNA/LNP technology platform, related R&D pipelines, and global research plans. Board Chairman Wu Yifang stated that the company aims to join the top tier internationally in the mRNA field.

Shortly before the R&D Day, the world's first personalized neoantigen mRNA cancer vaccine, Intismeran Autogene, achieved a positive endpoint in Phase III clinical trials, pushing the entire sector past a critical validation threshold. For Everest Medicines' EVM16, its technical approach and clinical development strategy are similar to those of Intismeran Autogene; the latter's Phase III success as a global benchmark provides clinical validation and a reference for this technical path.

In terms of platform layout, Everest Medicines is advancing coordinated development of its proprietary AI neoantigen sequence prediction algorithm and mRNA/LNP technology, having established a cutting-edge pipeline covering personalized neoantigen vaccines, off-the-shelf tumor vaccines, immunomodulatory vaccines, and in vivo CAR-T. Two former Moderna core scientists who were deeply involved in the development of Intismeran Autogene have joined the company, which is expected to further strengthen the company's global R&D capabilities and international collaboration layout for its mRNA technology platform.

Sector Just Achieved Phase III Validation

Before the R&D Day was held, the clinical development of personalized neoantigen mRNA cancer vaccines had just crossed a key threshold. The INTerpath-001 Phase III study, presented at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, showed that Intismeran Autogene (V940/mRNA-4157) combined with pembrolizumab, used as adjuvant therapy for completely resected high-risk Stage IIb–IV cutaneous melanoma patients, significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) compared to pembrolizumab alone, reducing the risk of recurrence or death by 42% and the relative risk of distant metastasis or death by 38%. This is the first individualized neoantigen therapy to achieve positive results in a Phase III trial.

Industry observers believe these results represent the first large-sample randomized controlled study validating the synergistic potential of "personalized neoantigen vaccines + immune checkpoint inhibitors" in reshaping the tumor immune microenvironment and inducing long-term immune memory, bringing the clinical development of personalized neoantigen mRNA vaccines into a new phase. At the same time, the study population, tumor types, and treatment settings still have clear boundaries, and the clinical value of long-term clinical benefits still warrants continued attention and expectation. Additionally, Intismeran Autogene is being explored in adjuvant treatment after resection of pancreatic ductal adenocarcinoma, providing new clinical research evidence for extending this technical path to other tumor types.

Professor Shen Lin, Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital and Chairman of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology, and Professor Lu Shun of Shanghai Chest Hospital Affiliated with Shanghai Jiao Tong University School of Medicine and Director of the Shanghai Lung Tumor Clinical Medical Center, both believe that the development path of therapeutic cancer vaccines differs from traditional anti-tumor drugs, and their mechanisms of action and immune response characteristics make early-stage and curative treatment settings worth exploring. The two experts further noted that beyond postoperative adjuvant therapy, expansion to neoadjuvant therapy and other earlier treatment settings, as well as exploring potential applications in first-line treatment, also deserve further evaluation through clinical research. For advanced patients, appropriate combination strategies and potentially benefiting populations need to be explored based on tumor burden, immune microenvironment, and prior treatment history.

For Everest Medicines' pipeline candidate EVM16 in the same sector, its technical approach and clinical development strategy are similar to those of Intismeran Autogene; the latter's Phase III success as a global benchmark provides clinical validation and a reference for this technical path. As a proprietary mRNA personalized neoantigen therapeutic cancer vaccine developed by Everest Medicines, EVM16 has completed its first-in-human clinical data readout, demonstrating good safety, tolerability, significant immunogenicity, and positive preliminary efficacy signals, with some data already presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

As the principal investigator of the investigator-initiated trial (IIT) for Everest Medicines' EVM16, Professor Shen Lin noted that the preliminary results of EVM16's first-in-human clinical trial in patients with advanced solid tumors showed good safety and tolerability, with preliminary immune activity signals observed, preliminarily validating the clinical value of EVM16 in achieving tumor immune activation through neoantigen-driven T-cell responses. "This gives us confidence in exploring this technical direction in gastrointestinal tumors. The next key step is to further accumulate clinical data and identify more suitable patient populations and combination treatment strategies."

Professor Lu Shun stated at the R&D Day that mRNA personalized therapeutic cancer vaccines, as a novel treatment modality, have changed the approach to cancer treatment and provided a new technical path for tumor immunotherapy. He particularly emphasized that in early-stage cancer and curative treatment settings, for patients who have undergone surgery or other curative treatments but still face recurrence risk, how to translate immune responses into reduced recurrence risk is a direction worthy of focused exploration for therapeutic cancer vaccines.

According to the company's disclosed R&D plans, EVM16 will add indication expansion cohorts based on the Phase Ia study to further explore its clinical efficacy, and the company plans to submit a U.S. IND application in the first half of 2027.

Aiming to Join the Top Tier Internationally in mRNA

From personalized neoantigen vaccines to off-the-shelf tumor vaccines, mRNA technology is broadening the R&D path for tumor immunotherapy and gradually extending to areas such as in vivo cell therapy. At the R&D Day, Dr. Lakshmi Srinivasan, Senior Vice President and Head of Translational Medicine at Everest Medicines, and Dr. Brandon Coder, Vice President of Translational Science and Early Research, participated in the forum, providing systematic presentations on cutting-edge mRNA tumor treatment technology, the company's proprietary AI+mRNA/LNP technology platform development, pipeline layout, clinical development of key projects, and manufacturing.

Notably, both individuals previously worked at Moderna and participated in the core R&D and clinical translation of the personalized neoantigen mRNA therapy Intismeran Autogene (V940/mRNA-4157). Their joining has been viewed by observers as a signal of Everest Medicines accelerating its overseas clinical layout. Dr. Lakshmi Srinivasan, who previously served as Moderna's Head of Oncology Translational Medicine, pointed out that global mRNA cancer treatment R&D has formed multiple directions including personalized neoantigen vaccines, off-the-shelf tumor vaccines, and immunomodulatory vaccines; in vivo mRNA applications are also moving from proof-of-concept to clinical practice. Combining global R&D progress, she specifically analyzed early explorations of related vaccines in solid tumors such as melanoma and pancreatic ductal adenocarcinoma, and noted that antigen selection, patient screening, delivery efficiency, and manufacturing are important links in advancing clinical translation.

Dr. Lakshmi Srinivasan stated, "mRNA/LNP technology has programmability and application flexibility, enabling exploration of multiple tumor treatment paths through different antigen designs and delivery strategies." In the future, the accuracy of antigen prediction, delivery efficiency, and the production cycle and delivery capability of personalized products will be key to advancing clinical translation of the technology.

Everest Medicines' R&D strategy aligns with global mRNA/LNP therapy development trends. Based on its current layout, the company's proprietary mRNA platform supports multiple cancer vaccine products including personalized tumor vaccines, off-the-shelf TAA vaccines, and immunomodulatory vaccines (IM), with the potential for combination with other treatment modalities and for combined application among themselves. The company's proprietary AI neoantigen sequence prediction algorithm can screen and predict potential neoantigens in patients' tumors. In addition to point mutations, insertions and deletions, and gene fusions, the algorithm is also exploring potential neoantigen sources such as alternative splicing, viral sequences, and endogenous retroviral sequences.

Everest Medicines Board Chairman Wu Yifang stated, "mRNA is a frontier technology field with important strategic value. Since the company initiated its layout in 2021, we have maintained strategic focus, continuously invested in R&D, and advanced platform development. We have now formed an end-to-end technology platform covering AI algorithms, antigen design, delivery technology, process development, and manufacturing, which supports the R&D of therapeutic cancer vaccines and in vivo CAR-T, among other directions. In the future, the company will continue to invest in R&D, talent development, and technological innovation to drive iterative upgrades of its proprietary technology platform." He acknowledged that China has comprehensive advantages in clinical resources, investigator-initiated clinical research, professional talent, R&D efficiency, and manufacturing costs. Based on this, the company will integrate international scientific resources with China's clinical and industrial advantages in its global layout, consolidating its domestic leading position while promoting R&D achievements to international markets, striving to join the top tier internationally in the mRNA field.

Everest Medicines Chief Executive Officer Luo Yongqing stated, "Over the past five years, the company's mRNA technology platform has gone through a development journey from technology introduction and clinical development experience accumulation to independent R&D and continuous iteration. Through the global Phase II clinical study of the PTX-COVID19-B COVID-19 vaccine, the company accumulated human immunogenicity, safety, and clinical development experience. Since then, the company has further advanced independent technology R&D, continuously iterated algorithms and delivery systems, established end-to-end capabilities across the mRNA platform value chain, and achieved preliminary positive clinical progress in projects such as personalized therapeutic cancer vaccines. In the future, the company will continue to advance the development of automated, modular production systems, shorten production cycles, and optimize costs to support global clinical development and subsequent industrialization of innovative therapies."

Currently, EVM14 has received IND approval in both China and the United States, and EVM16 has entered early-stage clinical research. The company is also extending mRNA/LNP technology to the in vivo CAR-T field, delivering CAR mRNA through its proprietary targeted lipid nanoparticles (tLNPs) to explore direct generation of CAR-T cells within patients, with related efforts covering autoimmune diseases and oncology.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment